Table 1. Cohort Characteristics.
| Characteristic | Mitomycin group (n=61) | Oxaliplatin group (n=60) | p Value |
|---|---|---|---|
| Follow-up, y | 3.2 | 3.9 | 0.14 |
| Sex, female, n (%) | 36 (59) | 33 (55) | 0.72 |
| Race, n (%) | 55 (90) | 56 (93) | 0.74 |
| Age, y, n (%) | 54.6 (14.0) | 55.2 (12.5) | 0.83 |
| PCI, n (%) | 18.0 (10.0) | 17.9 (9.4) | 0.94 |
| Resection status, n (%) | |||
| R0 | 13 (21) | 14 (23) | 0.35 |
| R1 | 20 (33) | 23 (38) | |
| R2a | 24 (39) | 15 (25) | |
| R2b | 4 (7) | 6 (10) | |
| R2c | 0 | 2 (3) | |
| Site, n (%) | 0.58 | ||
| MD Anderson | 5 (8) | 8 (13) | |
| University of Pittsburgh | 6 (10) | 4 (7) | |
| Wake Forest University | 50 (82) | 48 (80) | |
| Pathology, n (%) | 0.54 | ||
| Low grade | 40 (68) | 42 (74) | |
| High grade | 19 (32) | 15 (26) |
PCI, percutaneous coronary intervention.